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Abstract The aim of this study was to analyze cutaneous
pain threshold (CPT) during the interictal phase in head-
ache patients, and the relationships between headache
frequency and analgesic use. A consecutive series of 98
headache patients and 26 sex- and age-balanced controls
were evaluated. Acute allodynia (AA) was assessed by
Jakubowski questionnaire, and interictal allodynia (IA) by
a skin test with calibrated monofilaments. AA is widely
known as a symptom more present in migraine than in TTH
spectrum: in our study this was confirmed only in cases of
episodic attacks. When headache index rises towards
chronicization, the prevalence of AA increases in both
headache spectrums (v2 13.55; p \ 0.01). AA was associ-
ated with IA only in cases of chronic headache. When
headache becomes chronic, mostly in presence of medi-
cation overuse, interictal CPT decreases and IA prevalence
increases (v2 20.44; p \ 0.01), with closer association than
AA. In MOH patients there were no significant differences
depending on the diagnosis of starting headache (migraine
or tension type headache) and, in both groups, we found the
overuse of analgesics plays an important role: intake
of more than one daily drug dramatically reduces the
CPT (p \ 0.05). Thus, when acute allodynia increases
frequency, worsens or appears for the first time in patients
with a long-standing history of chronic headache, it could
reasonably suggest that the reduction of CPT had started,
without using a specific practical skin test but simply by
questioning clinical headache history. In conclusion, these
results indicate that the role of medication overuse is more
important than chronicization in lowering CPT, and sug-
gest that prolonged periods of medication overuse can
interfere with pain perception by a reduction of the pain
threshold that facilitates the onset of every new attack
leading to chronicization.
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Introduction
Allodynia is an abnormal sensory condition during which
normally innocuous stimuli are felt as painful. Sensitivity
changes, during headache attacks, have shown by common
symptoms like, a feeling of discomfort when patients wear
tight-fitting clothing, necklaces, glasses or when hair is
bound; or, also, when exposed to excessive heat or cold.
Migraineurs, during their attacks, highlight a decreased
pain threshold to non-noxious thermal and mechanical
stimulation of skin, frequently referred as cutaneous allo-
dynia. Using quantitative and semi-quantitative sensory
testing techniques, Burstein et al. have demonstrated the
gradual development of cutaneous allodynia in subjects
with episodic migraine after the onset of their migraine
attacks [1–4].
Animal studies support this hypothesis, in fact, the
application of an inflammatory soup to dura, in a rat model
of intracranial pain, followed by an innocuous stimulus,
generates a pronounced increase in neuronal firing patterns
in peripheral and central second-order neurons of the
trigemino-vascular system [5]. It has been suggested that
the time course and anatomic progression of this hyper-
sensitivity correlate with the time course of the develop-
ment of central sensitization. So, in patients with episodic
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migraine, cutaneous allodynia is likely to represent a
clinical correlate to the central sensitization.
Patients with frequent migraine usually evolve from
episodic attacks; the possible pathogenetic explanation for
this is that pain pathways become chronically sensitized
from repeated episodes of headache attacks [6–8].
This phenomenon could help to explain the clinical
observation that frequent episodic migraine develops into
transformed migraine (TM), and should therefore require
early prophylactic therapy to prevent the increase of
headache frequency, that is related to the headache
chronicization [6].
Moreover, given what has been shown to happen to pain
threshold during episodic migraine, one might expect that
patients with very frequent migraine would also have a
lower basal pain threshold (in absence of headache) than
normal subjects. Thus far, there have been no studies to
determine whether the cutaneous pain threshold (CPT) is
lowered during the interictal phase in patients who have
chronic headache (more than 15 days per month) in com-
parison to episodic headaches and the headache-free
population.
The aim of this study is to evaluate the relationship
between CPT and headache clinical characteristic with
regard to frequency, acute allodynia (AA), duration and
analgesic overuse.
Materials and methods
Patient population
We enrolled 102 patients, but only 98 performed all tests
and were evaluated for this study. All subjects were
outpatients that were selected in the Headache and Drug
Abuse Inter Department Research Centre at the Univer-
sity of Modena (Italy), after signing written informed
consent, between December 2008 and July 2009. All
data used were collected using patient’s medical history
and diary cards recorded in clinical folders that are
carefully kept in the Headache Centre. Patients who
meted the inclusion criteria were sent to the ward where
a trained doctor (Z.M.) filled clinical questionnaire and
performed the CPT test. The CPT tests were performed
in the morning. Patients with episodic headache were
pain-free for at least 48 h before testing, and sufferers
with chronic headache were tested in the morning before
taking any drug.
Control subjects were recruited from hospital staff by
the headache clinic nurse; these subjects were used rather
than normative data because it was unlikely that the con-
ditions of the normative trials could be exactly reproduced,
and it has been suggested that normative data in pain
threshold testing may be unreliable in different study
populations.
For each patient we have analyzed the subsequent three
parameters: (1) daily drug intake (DDI), number of drug
doses consumed every day; (2) headache index (HI),
number of days with headache attacks; (3) years of
chronicization (y. CHR), the time elapsed since the
beginning of chronicization. The daily drug intake and the
headache index were referred to 3-month period before
testing; while the period for chronicization was considered
when lasting more than 1 year.
This study was performed following the Helsinki Dec-
laration principles and approved by the University of
Modena and Reggio Emilia regulatory authorities.
Inclusion criteria
All patients were diagnosed by trained physicians accord-
ing to the ICHD-II criteria [9]. The following abbreviations
were used for the diagnoses: MIG = episodic migraine
with and without aura (ICHD 1.1 and 1.2); ETTH =
episodic tension type headache (ICHD 2.1 and 2.2);
CTTH = chronic tension type headache (ICHD 2.3),
MOH = medication overuse headache (ICHD 8.2). The
MOH group was also divided in two sub-groups according
to the type of starting headache and classified as TM-MOH
(TM = transformed migraine, following Silberstein [10])
when first diagnosis was in the migraine spectrum, or TTH-
MOH (TTH = tension type headache) when first diagnosis
belonged to the tension type spectrum. We included in the
control group age- and sex-matched healthy subjects.
Exclusion criteria
Patients younger than 18 years, patients with a secondary
headache, or headache associated to sensory loss/tingling,
neuropathy; or also patients with history of narcotic-seek-
ing behaviour, or, above all, patients unable to avoid
analgesic medication 12 h before the cutaneous pain
threshold test (CPT) were excluded from the study
protocol.
Allodynia questionnaire
Acute allodynia
In this study, this term is used and reported as a phenom-
enon that occurs during headache attack. AA was assessed
following Jakubowski’s allodynia questionnaire [11], and
this parameter was correlated with CPT and clinical fea-
tures of headaches and control groups. Specific questions
were used for confirming skin sensitivity in past attacks
and, according to these, patients were classified either as
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allodynic ([ or =1 symptom) or non-allodynic (zero
symptoms).
Cutaneous pain threshold test
In order to minimize bias, all patients and controls were
recruited by the headache clinic nurse; all the CPT
assessments were carried out during the interictal phase (in
absence of headache attack) by one investigator (Z.M.). To
investigate skin sensitivity, calibrated von Frey-like fila-
ments (Touch-Test Sensory Evaluators filaments, North-
Coast Medical Inc., CA) were applied sequentially in
increasing order for 2 s each to determine the initial (basal)
CPT, asking the patient when the touch becomes a painful
or very uncomfortable sting. Trials were repeated three
times and the filaments were used in each location in the
following calibration representing the respective, ascend-
ing forces in grams of each of the filaments (0.02, 0.04,
0.16, 1, 4, 6, 15, 60, 100, 180 and 300 g).
The test investigated three cutaneous areas: temple,
cheekbone and cervical areas (exploring first, second and
third divisions of the trigeminal nerve, respectively),
assessed bilaterally in random order, to measure the sen-
sitivity of skin outside the headache crisis.
Landmarks definition were: cervical, the skin over the
cervical and trapezius muscles, between C2 and C4 level;
cheekbone, the skin over periorbital area of zygomatic
bone; temple, the skin over the pars orbitalis of frontal and
sphenoid bones.
The test was always performed bilaterally out of crisis in
episodic headache and in presence of low pain (value 1) in
chronic headaches. In chronic patients we did not record a
unilateral pain during test. In fact, we did not find any
statistical difference either between sides in all groups, or
between sex. Moreover, as showed in Table 1 there were
no statistical differences within areas, so we decided to use
the mean values as an indicator of a generic skin threshold
of the head.
To establish pathological value for CPT, we used a
quantitative definition of allodynia, the same as used in
other studies [1, 11, 12]. Since we measured basal skin
sensitivity in the absence of headache, in cases of abnormal
reduction of CPT, we decided to use the term ‘‘interictal
allodynia’’ (IA). Using this ‘‘cut-off’’ method, individual
patients were identified as having IA to mechanical stimuli
when the three tested areas showed a mean overall CPT 1
or more standard deviation (SD) less than the basal mean
CPT, in the same areas of control subjects.
Our study has some limitations as the choice of controls
was from the hospital staff. In fact, these subjects could
have more awareness on nociceptive tests and were
younger as patients, but it was reasonable to perform the
test in the same way in patients and controls than compare
results with literature data. We are aware of the poor sta-
tistical power of so small a group of controls, but it is
reasonable to use a control group to define cut-off values,
unbiased between sites. The use of one SD as parameter
was used by Burstein et al. [1], but it could be discussed.
Statistical analysis
Continuous variables (age, y.CHR, HI, DDI and CPT) were
expressed as mean ± standard deviation. To compare CPT
values between controls, headache groups and subcategory
of headache patients’ features, we used independent
unpaired samples (with unequal variances) t test and
Bonferroni correction for multiple comparison; all p values
were two-sided. A sample mean comparison test was used
to indicate the normal CPT, useful to get an arbitrary
quantitative definition of cutaneous IA. To compare the
prevalence of AA and IA and estimate the degree of
association with headaches and conditions, data were
analyzed by Chi-Square Test of Association, Odds Ratio
and, in case of low sample, by Fisher Exact Probability
Test. To correlate CPT values with DDI, y.CHR and HI,
we used the Pearson correlation test. One-way ANOVA for
Table 1 Interictal mean CPT values recorded by CPT test with calibrated monofilaments
Group Temple Cheekbone Neck
Mean ± SD (g) p Mean ± SD (g) P Mean ± SD (g) p
CTRL 127.7 ± 75.6 NA 130.7 ± 76.1 NA 106.1 ± 59.5 NA
ETTH 70.3 ± 56.9 0.005 67.9 ± 56.9 0.004 80.7 ± 58.5 0.14
MIG 62.3 ± 72.6 0.004 61.6 ± 73.2 0.003 90.4 ± 91.2 0.49
CTTH 38.1 ± 55.7 \0.001 40.9 ± 58.2 \0.001 71.9 ± 60.2 0.13
MOH 19.7 ± 31.8 \0.001 12.6 ± 28.6 \0.001 29.4 ± 37.2 \0.001
TM-MOH 18.6 ± 23.2 \0.001 8.1 ± 11.6 \0.001 29.9 ± 42.7 \0.001
TTH-MOH 21.5 ± 42.9 \0.001 19.9 ± 43.5 \0.001 28.5 ± 27.6 \0.001
Student’s t test, p versus CTRL
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multiple comparison was used to compare CPT levels and
type of medication. STATA software (version 10, StataCorp
LP, TX, USA) was used to perform statistical analyses.
Results
Demographic data
98 patients aged between 19 and 65 years (mean ± SD =
44.4 ± 14.5); 72 F (aged 43.1 ± 14.4) and 26 M (aged
47.8 ± 14.7) were divided in to 4 main groups: ETTH,
CTTH, MIG and MOH. The MOH group was divided in
two subgroups: transformed migraine (TM), if starting
headache was migraine or tension type headache (TTH), if
initial headache was tensive.
The control group of 26 subjects was aged between 18
and 63 (40.2 ± 18.2); 9 M and 17 F, aged 43.9 ± 16.7 and
38.2 ± 19.1, respectively. There were no sex differences
between male and female so data were omitted. Data are
summarized in Table 2.
Allodynia
The percentages of patients resulting positive at the allo-
dynia questionnaire (AA) and positive at the CPT (IA) are
reported in Table 3.
A more detailed analysis showed that IA is closely
associated with the chronic form of headache, more than
AA [IA (OR = 7.82, 95% CI 3.42–23.64); AA (OR = 4.9,
95% CI 2.06–12.01)].
Questionnaire results
Taking into account all patients, AA prevalence was higher
in chronic (78.2%) than episodic headaches (41.8%) (v2
13.55; p \ 0.01). AA was more frequent in migraine form
(75%) than in tension type form (50%) (v2 7.25; p \ 0.01).
A deeper analysis showed that only in cases of episodic
attacks AA prevalence was higher in migraine (66%) than
in tension type headache (18%); (Fisher exact probability
test p = 0.001). In chronic headache group (both CTTH
and MOH) the difference of AA between TM-MOH (81%)
and tension type headache (CTTH and TTH-MOH (75%)
disappeared (see Table 3).
Cutaneous pain threshold
Pathological values of CPT were assessed for each area:
temples \56 g; cheekbone \52 g; neck \46 g, following
the cut-off method, calculated as 1 SD lower than mean
CPT in the control group. While there were no statistical
differences between mean CPT values of the three tested
areas, to estimate IA prevalence we assessed a pathological
value (\56 g) for the whole generalized mean CPT of
overall areas. This cut-off threshold value was statistically
significant, analyzed and validated by one sample com-
parison t test (p \ 0.01). Subjects were considered as
having IA, if mean CPT of overall areas was lower than
\56 g at the CPT.
Only chronic headaches showed pathological mean CPT
values, and IA prevalence was higher in chronic headaches
(83.6%) than episodic headaches (39.5%) (v2 20.44;
p \ 0.01).
CPT values (mean ± SD) in the three tested areas of all
headache groups and statistical significance versus CTRL
(Student’s t test p value) are collected in Table 1. Figure 1
shows the overall areas of mean CPT values of CTRL and
all headache groups, with significant statistical differences
between groups. No statistical differences were found
either between male and female or between sides (dx vs.
lf), so data were omitted.
Table 2 Demographic data
Group N Age Male (N) Female (N)
CTRL 26 40.2 ± 18.2 9 17
ETTH 22 37.0 ± 11.4 7 15
MIG 21 38.2 ± 12.3 4 17
CTTH 11 46.6 ± 20.0 3 8
MOH 44 50.3 ± 12.8 12 32
TM-MOH 27 48.1 ± 24.4 8 19
TTH-MOH 17 35.4 ± 20.7 4 13
TM-MOH and TTH-MOH are subgroups of MOH
MIG episodic migraine with and without aura (ICHD 1.1 and 1.2),
ETTH episodic tension type headache (ICHD 2.1 and 2.2),
CTTH chronic tension type headache (ICHD 2.3), MOH medication
overuse headache (ICHD 8.2), TM-MOH MOH started as migraine,
TTH-MOH MOH started as tension type headache
Table 3 Clinical data
Group n HI y.CHR AA % (n) IA % (n)
CTRL 26 – – – (0) – (0)
ETTH 22 0.14 ± 0.15 – 18.2% (4) 27.2% (6)
MIG 21 0.19 ± 0.13 – 66.6% (14) 52.3% (11)
CTTH 11 0.82 ± 0.18 6.9 ± 6.7 81.8% (9) 72.7% (8)
MOH 44 0.88 ± 0.15 15.6 ± 13.6 77.2% (34) 86.4% (38)
TM-MOH 27 0.85 ± 0.34 17.4 ± 15.2 81.4% (22) 85.1% (25)
TTH-MOH 17 0.72 ± 0.42 3.3 ± 3.9 70.6% (12) 88% (15)
TM-MOH and TTH-MOH are subgroups of MOH. Numbers in
brackets
HI headache index, y.CHR = years of chronicization, AA acute
allodynia estimated by questionnaire, IA interictal allodynia evaluated
by CPT test
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Mean CPT values of all headache groups were statisti-
cally more significantly reduced than CTRL, and mean
difference between CTRL and patients groups ranged from
48.54 g (ETTH) to 102.87 g (TM-MOH). The MOH group
presented the lowest absolute CPT values compared to
every group, in every area (p \ 0.01). ETTH, MIG and
CTTH groups, compared to CTRL, showed significant
reduced mean CPT only in temple and cheekbone areas
(p \ 0.01); while sensitivity of the neck area was similar to
the CTRL group.
A more detailed evaluation was performed for the MOH
group: no statistical differences were found between the
two subgroups TM-MOH and TTH-MOH.
Taking into account all headache sufferers, there was
a negative linear correlation between HI and CPT, with
statistical significance (r = -0.43; p \ 0.01). In fact,
chronic headaches (26.5 ± 35.2 g), but not episodic
headaches (72.2 ± 62.9 g), showed extremely reduced
mean CPT values (p \ 0.01).
The duration of chronicization is associated with CPT
reduction: taking into account all chronic patients (CTTH
and MOH, n = 55), we found a negative linear correlation
between mean CPT and y.CHR (r = -0.431; p = 0.01).
The mean CPT in each clinical headache group is reported
in Fig. 1
The comparison between patients with and without drug
abuse (CTTH and MOH groups) showed that presence of
medication overuse played a role in CPT reduction, similar
to chronicization. There was strong association of medi-
cation overuse with presence of IA (v2 16.9; p \ 0.01),
stronger (approximately double) than the association with
presence of AA (v2 7.67; p \ 0.01). In the whole MOH
group, mean CPT values decreased depending on
the number of DDI, with negative linear correlation (r =
-0.436; p \ 0.01). As shown in Fig. 2, patients who took
more than one analgesic medication per day showed the
lowest mean CPT values (Bonferroni Test: p \ 0.05 A vs.
B and C). Moreover, the mean CPT of patients with DDI
equal to or less than 1 (52.5 ± 32.1 g) was lower than the
CTRL group (p \ 0.01), not being too far from normal
value ([56 g).
There were three main groups of abuse, divided
according to the type of primary abused drug: NSAID
(n = 18; 41%), mixture drugs (n = 16; 36%) and triptans
(n = 10; 23%) in Fig. 3. The mean DDI in the group of
abusers (MOH) was 2.6 ± 1.8; the highest DDI rate was
for mixtures 3.42 ± 3.03 followed by triptans 2.60 ± 1.76
and then by NSAID 1.97 ± 1.11, but no statistical differ-
ences were found within these groups on DDI (Bonferroni
t test).
We also analyzed the relation between CPT and the
types of analgesic drugs overused by patients. The lowest
mean CPT was for mixture (13.8 ± 17.5 g), followed
by triptans (19.44 ± 21.46 g) and then by NSAID
(27.3 ± 34.7 g) but, probably due to the paucity of data, no
statistically significant differences were found in mean
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CPT between the different types of primary abuse associ-
ated with the MOH group.
Relationships between AA, IA and CPT
To investigate the relationship between AA and IA, we
compared the results of the two tests (questionnaire and
CPT) across the different groups and features of headaches.
In cases of episodic headaches, there was no significant
difference between mean CPT values depending on the
presence (57.2 ± 70.3 g) or the absence (83 ± 55.9 g) of
AA, both with normal interictal skin sensitivity.
Only in cases of chronicization did subjects with AA
(21.4 ± 33.2 g) show lower mean CPT than subjects
without AA (44.6 ± 37.6 g) and both showed allodynic
mean CPT values (p \ 0.05).
The rate of simultaneous presence of both AA and IA
was higher in chronic than episodic headaches (v2 = 16.4;
OR = 5.77.95% CI 2.4–13.9; p \ 0.0005).
Discussion
The primary objective of this study was to estimate pain
threshold during the interictal phase, in different types of
episodic and chronic headaches, comparing four groups of
headache patients with a sex- and age-matched control
group. We assessed, also, the prevalence of allodynia
during attacks and recorded CPT in scheduled cranial-
facial areas outside headache crisis, to determine if they
were altered, and to correlate the variation of this param-
eter to the time course of the headache itself.
Epidemiological studies identify the following major
risk factors for worsening of migraine: frequency of
headache attacks at baseline, obesity, medication or caf-
feine overuse, sleep disorders (including sleep disordered
breathing), stressful life events and depression [13–17].
Although the first neurological event leading to migraine
pain is still not completely understood, it has been suggested
that dysfunction of the brainstem involved in the modulation
of craniovascular afferents may lead to activation of
ascending and descending pathways with onset of a peri-
meningeal vasodilatation and neurogenic inflammation [18].
Preclinical studies show that drug abuse can induce pro-
nociceptive neuroadaptive changes in the oro-facial divi-
sion of the trigeminal ganglia that persist even after dis-
continuation of drug treatment. Additionally, medication
abuse can elicit an increase of descending facilitatory
influences that may amplify inputs from trigeminal affer-
ents leading to behavioural hypersensitivity clinically evi-
dent as cutaneous allodynia [19, 20].
Prevalence of AA, as previously reported in other
studies, was higher in patients with MIG (66.6%) than
ETTH (18.2%), but this difference was present only in
episodic headache. When headache becomes chronic, the
differences disappear: TM-MOH (81%) and chronic form
of TTH (75%) (CTTH and TTH-MOH) showed similarly
high percentages of AA. Following the Jakubowski allo-
dynia questionnaire we found comparable prevalence as in
literature, whereas we did not find difference between sex
[1, 12, 21, 22] (see Table 3). These observations are con-
firmed by a prior study, performed using a specific ques-
tionnaire sent by post to a random sample of 24,000
headache sufferers, previously identified from the popula-
tion, in which Bigal showed that the prevalence of acute
allodynia was significantly higher in transformed migraine
(TM = 68.3%) than in episodic migraine (63.2%,
p \ 0.01) and that it is more common and more severe in
migraine and transformed migraine than in other primary
headaches [21].
In our study we found that the skin sensitivity (CPT) in
patients with episodic headache rises only during headache
attack (AA), after which it reverts to normal values.
Patients with MIG and ETTH showed similar mean CPT
values during the interictal phase.
An increase of the interictal skin sensitivity (IA) was
evident in chronic headache. In fact, while in episodic
headache, patients with and without AA showed normal
and similar mean CPT values, in chronic headache,
patients with AA showed lower levels of mean CPT than
those without AA. So, the AA may be suggestive of
interictal CPT reduction only in case of chronicization
(see Table 3).
When episodic headaches start AA may occur without
IA. The contemporary presence of AA and IA were found
only in chronic headache, especially in patients with
medication overuse.
The chronicization in patients that suffer of headache
modifies the pattern of headache itself, the sensitivity and
the transmission of pain.
Pain is not only the expression of a nociceptive input,
but the perception of balanced peripheral and central
stimuli, often affected by emotional and cognitive influ-
ences [23–25].
This is more evident if the descending pain modulatory
system is affected; in fact, the repetitive activation of
trigeminovascular neurons reduce the activity of the peri-
aqueductal gray (PAG) that is part, together other brain
regions (frontal lobe, anterior cingulate cortex, amygdala,
hypothalamus, rostral ventromedial medulla) of the ana-
tomical network able to regulate nociceptive processing;
silent brain damage and increase in iron concentration in
deep nuclei are more frequent in patients with chronic
migraine [26, 27].
Our results underline that high frequency of headache
attacks task a significant reduction of CPT; CPT decrease if
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chronic headache lasts for some years, at least, 5–10 years.
After this period CPT level remains constantly low. The
pain temporal threshold is reduced in patients with medi-
cation overuse headache and improves after medication
overuse was discontinued [28]
The role of medication overuse/abuse in reducing pain
threshold has been suggested in previous studies [21, 22].
In these patients the link between pain and homeostasis is
modified, as confirmed by observation that the vanilloid
receptors, TRV1, cation channels that act as a polymodal
detector of pain producing stimuli like capsaicin and pro-
tons (pH \ 5.7), are tonically activated [29]. The central
latent sensitization induced by the continuous increase in
drug consumption could provide a mechanistic basis for
evolution of migraine in medication overuse headache
[4, 19, 30, 31].
In our data we have found a close connection between
the number of analgesics used daily and the CPT (Fig. 2),
whereas our limited sample does not allows us to draw
conclusions about the effect on CPT of different analgesics
used.
In conclusion medication overuse plays a role in lowering
CPT more than headache chronicization itself, but further
studies are needed. A prolonged period of medication abuse
may increase the incidence of CSD events, or consequence of
CSDs, to initiate signalling in the trigeminovascular system
to enhance the frequency of migraine headaches, and, con-
sequently, to promote persistent cephalic and extracephalic
cutaneous allodynia [32].
It is difficult to discriminate the influence of length of
chronicization and the possible effect of anti-migraine
drugs. There are a number of studies on this argument, but
there are not evidences that separate the chronicization
from the activity of analgesic drugs. In our study we
reported these new data: it seems that independently from
patient’s histories, the most used drugs and concomitant
factors (both psychological and physical), the association
between chronic headaches and daily drug use lowered the
CPT.
Finally, we are aware that one of the major limitations of
this study is due to the paucity of the CTTH group and the
lack of psychological pattern of drug abuser. Chronic
patients without medication overuse are infrequent and a
wider group could be really helpful to quantify the differ-
ence between the importance of medication overuse and
chronicization in causing CPT reduction.
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